Diffusion Pharmaceuticals Inc.

6.91-0.2200-3.09%Vol 28.76K1Y Perf 803.68%
Jun 24th, 2022 16:00 DELAYED
BID6.50 ASK7.24
Open7.08 Previous Close7.13
Pre-Market- After-Market6.92
 - -  0.01 0.14%
Target Price
40.00 
Analyst Rating
Hold 3.00
Potential %
478.87 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
4.81 
Earnings Rating
Strong Buy
Market Cap14.08M 
Earnings Date
10th Aug 2022
Alpha-0.07 Standard Deviation0.31
Beta1.64 

Today's Price Range

6.887.24

52W Range

5.1042.76

5 Year PE Ratio Range

-1.00-0.6000

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
-12.75%
1 Month
-9.44%
3 Months
2 478.36%
6 Months
1 671.79%
1 Year
803.68%
3 Years
138.28%
5 Years
-84.33%
10 Years
-99.88%

TickerPriceChg.Chg.%
DFFN6.91-0.2200-3.09
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022-1.75-2.22-26.86
Q04 2021-2.00-2.000.00
Q03 2021-2.00-6.00-200.00
Q02 2021-2.50-2.0020.00
Q01 2021-2.50-3.00-20.00
Q04 2020-3.00-3.000.00
Q03 2020-0.06-0.07-16.67
Q02 2020-0.06-0.10-66.67
Earnings Per EndEstimateRevision %Trend
6/2022 QR-1.7711.50Positive
9/2022 QR-2.07-3.50Negative
12/2022 FY-7.825.21Positive
12/2023 FY-6.917.87Positive
Next Report Date10th Aug 2022
Estimated EPS Next Report-1.77
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume28.76K
Shares Outstanding2.04K
Shares Float2.03M
Trades Count336
Dollar Volume204.14K
Avg. Volume234.83K
Avg. Weekly Volume64.31K
Avg. Monthly Volume38.48K
Avg. Quarterly Volume601.70K

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) stock closed at 6.91 per share at the end of the most recent trading day (a -3.09% change compared to the prior day closing price) with a volume of 28.76K shares and market capitalization of 14.08M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 10 people. Diffusion Pharmaceuticals Inc. CEO is Robert Joseph Cobuzzi.

The one-year performance of Diffusion Pharmaceuticals Inc. stock is 803.68%, while year-to-date (YTD) performance is 2165.57%. DFFN stock has a five-year performance of -84.33%. Its 52-week range is between 5.1 and 42.755, which gives DFFN stock a 52-week price range ratio of 4.81%

Diffusion Pharmaceuticals Inc. currently has a PE ratio of -0.70, a price-to-book (PB) ratio of 0.53, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -55.34%, a ROC of -57.21% and a ROE of -59.01%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Diffusion Pharmaceuticals Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.77 for the next earnings report. Diffusion Pharmaceuticals Inc.’s next earnings report date is 10th Aug 2022.

The consensus rating of Wall Street analysts for Diffusion Pharmaceuticals Inc. is Hold (3), with a target price of $40, which is +478.87% compared to the current price. The earnings rating for Diffusion Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Diffusion Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Diffusion Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 25.85, ATR14 : 0.63, CCI20 : -206.92, Chaikin Money Flow : 0.00, MACD : 0.13, Money Flow Index : 47.68, ROC : -10.84, RSI : 44.08, STOCH (14,3) : 2.34, STOCH RSI : 0.00, UO : 45.88, Williams %R : -97.66), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Diffusion Pharmaceuticals Inc. in the last 12-months were: Robert Joseph Cobuzzi (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
0 (0.00 %)
0
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0
Hold
1 (100.00 %)
1 (100.00 %)
0
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0
Strong Sell
0 (0.00 %)
0 (0.00 %)
0
Summary RatingHold
3.00
Hold
3.00
-
0.00

Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Inc is a clinical stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's lead product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM); Phase II pancreatic cancer; and metastatic brain cancer.

CEO: Robert Joseph Cobuzzi

Telephone: +1 434 220-0718

Address: 1317 Carlton Avenue, Charlottesville 22902, VA, US

Number of employees: 10

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

61%39%

Bearish Bullish

59%41%

News

Stocktwits